R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

January and February this year weren't a story of a few dominant megadeals, but rather a dense constellation of cross‑disciplinary alliances.

R&D

Read how Jan-Feb '26 offered a revealing cross-section of how R&D is evolving across therapy areas.

R&D

Andrew Mackinnon, senior vice president and executive general manager at Medable, discusses leveraging AI to transform & accelerate development.

R&D

As rare disease becomes more competitive, information parity is disappearing.

R&D

Net Treatment Benefit provides a formal framework to integrate multiple prioritised outcomes into a single measure of overall treatment effect.

R&D

Innovative trial designs that harness data augmentation, RWD, and the power of AI are enabling a new era of rare disease research.